Aktis Oncology's AKY-2519 Shows Promising Tumor Uptake in Early Human Trials
Event summary
- Aktis Oncology reported first-in-human clinical imaging and dosimetry data for AKY-2519, showing robust tumor uptake and limited normal tissue exposure in B7-H3 expressing tumors.
- Data will be presented at the 2026 ASCO Annual Meeting in two poster presentations.
- AKY-2519 demonstrated favorable predicted absorbed doses in critical normal tissues compared to approved radiopharmaceuticals.
- Aktis plans to initiate a second Phase 1b trial of AKY-2519 in other B7-H3 expressing solid tumors in the second half of 2026.
The big picture
Aktis Oncology's AKY-2519 represents a strategic push into targeted radiopharmaceuticals for a broader range of tumor types beyond those addressed by current technologies. The positive early data positions Aktis to compete in the growing market for radiopharmaceuticals, particularly in indications like mCRPC where existing options may have limitations. The company's proprietary miniprotein radioconjugate platform aims to deliver high tumor penetration and rapid clearance from normal tissues, addressing significant unmet needs in oncology.
What we're watching
- Clinical Development
- The pace at which Aktis can advance its Phase 1b trials and generate preliminary data for AKY-2519 in mCRPC and other solid tumors.
- Competitive Positioning
- Whether AKY-2519's differentiated profile can position it as a strong competitor against existing radiopharmaceuticals in the B7-H3 expressing tumor market.
- Regulatory Pathway
- How the favorable initial data will influence the regulatory strategy and potential approval timeline for AKY-2519.
Related topics